Summit Therapeutics Inc.
SMMT
주식 순위
#1661
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
주가
$16.14
마지막 동기화: 2026-10-20
시가총액
$12.87B
변동 (1일)
3.65%
변동 (1년)
-13.88%
국가
US
거래 Summit Therapeutics Inc. (SMMT)
카테고리
Healthcare
Summit Therapeutics Inc. (SMMT)의 수익
Jun 2026 기준 수익 TTM: $-856.04M
Summit Therapeutics Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-856.04M입니다. 2023년에 회사는 $-615.87M의 수익을 올렸으며 이는 2022년의 수익 $-78.78M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Summit Therapeutics Inc.의 수익 기록 (2004 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-856.04M | 286.80% |
| 2024 | $-221.32M | -64.06% |
| 2023 | $-615.87M | 681.74% |
| 2022 | $-78.78M | -11.08% |
| 2021 | $-88.60M | 67.46% |
| 2020 | $-52.91M | 40.45% |
| 2019 | $-37.67M | -21.65% |
| 2018 | $-48.08M | 18.85% |
| 2017 | $-40.45M | 22.47% |
| 2016 | $-33.03M | 73.25% |
| 2015 | $-19.07M | 4.94% |
| 2014 | $-18.17M | 58.92% |
| 2013 | $-11.43M | 54.03% |
| 2012 | $-7.42M | -50.39% |
| 2011 | $-14.96M | 0.25% |
| 2010 | $-14.92M | -44.98% |
| 2009 | $-27.12M | -37.83% |
| 2008 | $-43.63M | 223.51% |
| 2007 | $-13.49M | 249.34% |
| 2006 | $-3.86M | 1,451.88% |
| 2005 | $-248.74K | 226.26% |
| 2004 | $-76.24K | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | -716.20% |
US
|
|
| $-3.09B | 260.61% |
US
|
|
| $-4.02B | 369.16% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -327.87% |
NL
|
